公开(公告)号：EP1988078B1

公开(公告)日：2012-10-17

申请号：EP08075675.2

申请日：1997-04-29

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： Costanzo, Michael J. ,  Hoekstra, William J. c/o Ortho-McNeil Pharmaceutical Inc. ,  Maryanoff, Bruce E.

IPC分类号： C07D213/55

CPC分类号： C07F7/0812 ,  C07D211/60 ,  C07D213/55 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14

公开(公告)号：EP2319528A3

公开(公告)日：2011-08-31

申请号：EP10184898.4

申请日：2003-09-18

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： Kaushansky, Kenneth ,  MacDonald, Brian R.

IPC分类号： A61K38/18

CPC分类号： A61K38/196 ,  A61K35/28 ,  A61K2300/00

摘要： A method of increasing hematopoietic stem cell production is disclosed. The method includes administering a TPO mimetic compound to a subject. Pharmaceutical compositions including a TPO mimetic compound and a pharmaceutically acceptable carrier are also disclosed.

公开(公告)号：EP0716615B2

公开(公告)日：2009-10-21

申请号：EP94925757.0

申请日：1994-08-05

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： ROOS, Eric J. ,  CHIANG, Chia-Ming ,  HSU, Tsung-Min

IPC分类号： A61L15/24 ,  A61K9/70 ,  A61K31/56

CPC分类号： A61K9/7061 ,  A61K31/565 ,  A61K31/567

公开(公告)号：EP2016930A3

公开(公告)日：2009-09-02

申请号：EP08009460.0

申请日：2002-02-19

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： Degraw, Juli ,  Moriarty, Ann ,  Leturcq, Didier J. ,  Jackson, Michael R. ,  Peterson, Per A. ,  Heiskala, Marja

IPC分类号： A61K6/00

CPC分类号： C12N5/0636 ,  A61K39/0011 ,  A61K41/00 ,  A61K48/00 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55527 ,  A61K2039/55533 ,  A61K2039/55538 ,  C12N5/0601 ,  C12N2501/23 ,  C12N2501/515 ,  C12N2502/99 ,  C12N2510/00

摘要： T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.

公开(公告)号：EP1268421B1

公开(公告)日：2009-05-06

申请号：EP01920898.2

申请日：2001-03-29

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： BREITENBUCHER, J., Guy ,  CHAI, Wenying

IPC分类号： C07D209/12 ,  C07D403/12 ,  C07D401/12 ,  A61K31/404 ,  A61P25/28

CPC分类号： C07D401/12 ,  A61K31/423 ,  C07D209/12 ,  C07D403/12 ,  C07D471/04

摘要： The invention features pharmaceutically-active indoles that are substituted with phenyl, methods of making them, and methods of using them.

公开(公告)号：EP1330451B1

公开(公告)日：2008-01-23

申请号：EP01989314.8

申请日：2001-10-23

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： URBANSKI, Maud, J. ,  GUNNET, Joseph, W., Jr. ,  DEMAREST, Keith, T.

IPC分类号： C07D401/00

CPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14

摘要： The invention is directed to substituted benzimidazol-2-ones of Formula (I), wherein A, X, Y, m, n, R1, R2, R3, R4, and R5 are as described in the specification, which are useful as vasopressin receptor antagonists or Neuropeptide Y Modulators for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroke, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.

公开(公告)号：EP1035856B1

公开(公告)日：2007-01-10

申请号：EP98953282.5

申请日：1998-10-07

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： LOVENBERG, Timothy, W. ,  ERLANDER, Mark ,  HUVAR, Arne ,  PYATI, Jayashree

IPC分类号： A61K31/785 ,  C07K14/705 ,  C07K16/28 ,  C12N15/12

CPC分类号： C07K14/723 ,  A61K38/00

摘要： DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNAs have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

公开(公告)号：EP1401424B1

公开(公告)日：2006-11-29

申请号：EP02707927.6

申请日：2002-02-21

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： PLATA-SALAMAN, Carlos,R. ,  ZHAO, Boyu ,  TWYMAN, Roy,E.

IPC分类号： A61K31/27 ,  A61P25/18

CPC分类号： A61K31/325

摘要： This invention is directed to a method for preventing or treating psychotic disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of formula (I) and formula (II) wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

公开(公告)号：EP1248844B8

公开(公告)日：2006-10-25

申请号：EP99967490.6

申请日：1999-12-22

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： SPRINGER, Barry, A. ,  PANTOLIANO, Michael, W. ,  SHARP, Celia, M.

IPC分类号： C12N15/12 ,  C07K14/50 ,  A61K38/18

CPC分类号： C07K14/503 ,  A61K38/00 ,  C07K2319/00

公开(公告)号：EP0906091B1

公开(公告)日：2006-10-04

申请号：EP97919990.8

申请日：1997-03-27

申请人： Ortho-McNeil Pharmaceutical, Inc.

发明人： SOLL, Richard, M. ,  LU, Tianbao ,  FEDDE, Cynthia, L. ,  TOMCZUK, Bruce, E. ,  ILLIG, Carl

IPC分类号： A61K31/18 ,  A61K31/24 ,  A61K31/40 ,  A61K31/41 ,  A61K31/44 ,  A61K31/47 ,  A61K31/155 ,  A61K31/275 ,  C07C47/24 ,  C07C47/27 ,  C07C47/228 ,  C07C317/40 ,  C07D215/36 ,  C07C231/18

CPC分类号： C07D285/14 ,  C07C45/29 ,  C07C45/71 ,  C07C47/277 ,  C07C281/18 ,  C07C309/73 ,  C07C309/74 ,  C07C309/75 ,  C07C309/77 ,  C07C311/21 ,  C07C323/66 ,  C07C2601/02 ,  C07D213/71 ,  C07D215/36 ,  C07D217/02 ,  C07D231/18 ,  C07D233/52 ,  C07D317/40 ,  C07D333/34 ,  C07C47/575

摘要： Amidino and benzamidino compounds, including compounds of formula (I), wherein R?1-R4, R6-R9¿, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of formula (I).